Project Details
Description
PROJECT SUMMARY
Acute Myeloid Leukemia (AML) is a heterogeneous disease, with subtypes defined by a range of clinical,
morphological, cytogenetic, and molecular characteristics. This Core provides the projects with the resources to
study the human disease in various sub-types, allowing investigators to examine metabolic differences and
varying sensitivity to anti-leukemic agents. Specific Aims: Aim 1) Expand, maintain, and characterize leukemia
tissue banks at PSCI, UVA, and MSKCC. Banks provide cell samples from a broad variety of AMLs and normal
controls. Samples cryopreserved in many aliquots allow repeated interrogation. Cases are categorized according
to clinical data and genotyping. Core B will develop long-term culture propagation of primary hAML stem cells
for programmatic assays. Aim 2) Assess the safety and the maximum tolerated dose (MTD) and
pharmacokinetics (PK) of agents in vivo. Animal models for preclinical toxicity (dose escalation, MTD), and
pharmacokinetics assessment are in place at PSCI. Results from this Aim are critical for the development of
Program therapeutics. Aim 3) Develop and maintain animal models for testing Program-derived therapies. Our
published studies demonstrate promising data in a number of such models. Aim 3A. Provide NRGS (NOD-
Rag1null IL2rg null) cell line xenograft models for therapeutic studies (performed at PSCI). Transplantable
luciferase labeled AML cell lines grown as NRGS xenografts yield in vivo tumor monitoring and rapid readout of
efficacy (PSCI). Core B will provide and extend Standard of Care Models to compare to Program therapeutics.
Aim 3B. Provide transplantable, genetically engineered mouse models (GEMMs) of AML to test novel
therapeutics (performed at MSKCC and PSCI). Aim 3C. NRGS engraftment with Patient-Derived Xenografts
(PDXs) for confirmation and extension of data from other models (performed at PSCI and MSKCC). This Core
has developed an innovative technique for retroviral labeling primary AML which seems likely to expedite and
expand the efficiency of study of PDXs greatly. These various services provided to all projects are essential to
the success of the program.
| Status | Active |
|---|---|
| Effective start/end date | 9/1/25 → 8/31/26 |
Funding
- National Cancer Institute: $609,379.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.